Pure Global AI
NCT05740215Recruiting

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

A Multicenter, Open-label, Phase Ib/II Study on the Efficacy and Safety of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTDPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
F520
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shandong New Time Pharmaceutical Co., LTD
Location
Chongqing, China
Timeline & enrollment
Phase
Phase 1/2
Start date
May 23, 2022
End date
May 22, 2024
Enrollment
158 participants
Primary outcome

Serious adverse events,Adverse events,Dose-limiting toxicity (DLT),Maximum tolerated dose (MTD),Phase II recommended dose (RP2D).,Objective Response Rate (ORR)

Summary

This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520
 combined with lenvatinib in the treatment of patients with advanced solid tumors. About
 138~158 patients with advanced solid tumors plan to be enrolled in about 30 study sites of
 the study.
 
 Part I: Phase Ib study evaluating the safety and tolerability of F520 combined with
 lenvatinib in patients with advanced solid tumors.
 
 Part II: Phase II study of F520 combined with lenvatinib in endometrial cancer and cervical
 cancer.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05740215
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05740215 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shandong New Time Pharmaceutical Co., LTD and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 158 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.